Health Care · Laboratory Analytical Instruments

BRKR Bruker Corp SEC Filings & Insider Trading Activity 2026

company
CIK 1109354116 filings

BRKR at a glance

Bruker Corp (BRKR, SEC CIK 1109354) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Bruker Corp (BRKR) reported revenue of $3.4 billion (up 2.1% from FY2024) and a net loss of $8.6 million. Diluted EPS was -$0.15.
  • As of September 30, 2026, 34 institutional investment managers tracked by SignalX reported holding Bruker Corp (BRKR) shares worth $2.9 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Munch Mark on September 15, 2026 of 2,000 shares at $52.87 per share.
  • In the last 90 days, BRKR insiders reported 0 open-market purchases ($0) and 1 open-market sale ($106K) on Form 4, a net sale of $106K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$3.4B
+2.1% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$106K
13F holders
34 funds
$2.9B · +1 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 8.01 · Item 5.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors from the 2025 Form 10-K
  • Business performance remains exposed to previously disclosed risks affecting financial condition and operating results
  • Additional unknown or currently immaterial risks could materially adversely affect results

Management Discussion & Analysis

  • Q3 revenue $874.0M, up 1.6% YoY from $860.5M
  • GAAP gross margin 49.1% vs 44.1%; operating margin (10.4)% vs (6.0)%
  • BEST strongest growth, revenue $82.1M, up 11.2%; BSI NANO weakest, revenue $263.1M, down 1.3%
  • Operating cash flow $118.2M vs $(33.2)M; nine-month free cash flow $37.5M vs $(163.9)M
  • Outlook: cash and facilities sufficient for at least twelve months; tariffs and trade uncertainty threaten bookings, revenue and profitability

AI summary of the BRKR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 8.01: Other Events

  • Quarterly cash dividend: $0.05 per common share
  • Payable January 7, 2027, to shareholders of record December 21, 2026

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expansion from 11 to 12 directors, increasing governance capacity
  • Eicke Latz MD PhD joins effective January 1, 2027, serving Class II through the 2029 Annual Meeting

Item EX-99.1: Item EX-99.1

  • Dr. Eicke Latz joining Bruker’s board effective January 1, 2027
  • Scientific leadership in innate immunity, inflammation, proteomics, and molecular diagnostics
Filed Nov 5, 2026Full analysis →

Item 8.01: Other Events

  • Effective July 1, 2026, Bruker reorganized reportable segments from four legacy structures into four new operating segments
  • BSI BIOS expanded to include BioSpin, SciY, CST, Daltonics, Optics and Mimetas

Item EX-99.1: Item EX-99.1

  • Segment recast separates BioSpin into BIOS and BMID, improving comparability of operating performance
  • Six-month 2026 revenue $1,661.9M, up from $1,598.8M in 2025
Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Press release in Exhibit 99.1 contains the substantive financial figures and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 revenue $874.0M, up 1.6% YoY, but organic growth only 0.7%, signaling modest underlying demand
  • Non-GAAP operating margin expanded to 16.3% from 12.3%, while non-GAAP EPS rose 24.4% to $0.56

AI summaries of BRKR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BRKR

Don't miss the next BRKR filing

  • Alerts as it files. A push when BRKR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BRKR, by share count.
  • Ask anything. An AI agent that reads every BRKR filing and answers with sources.

BRKR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Munch MarkMSep 15, 2026-
Munch MarkSellSep 15, 2026$52.87
Munch MarkMSep 15, 2026$22.19
Pusch WolfgangSellAug 17, 2026$56.90
Srega JuergenAAug 15, 2026-
Prause BurkhardAAug 15, 2026-
Munch MarkFAug 15, 2026$57.70
Srega JuergenAAug 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$3.4B$3.4B
Gross Profit-$1.6B$1.6B
Operating Income-$253.1M$68.2M
Net Income-$113.1M-$8.6M
Gross Margin-49.0%45.9%
Op. Margin-7.5%2.0%
Net Margin-3.4%-0.3%
Balance Sheet
Total Assets$4.2B$5.8B$6.2B
Equity$1.4B$1.8B$2.5B
ROE-6.3%-0.4%
Per Share
EPS-$0.76$-0.15
Cash Flow
Operating CF-$251.3M$134.1M
CapEx-$115.3M$90.8M

Source: XBRL data in Bruker Corp (BRKR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BRKR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BRKR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202634$2.90B
Q2 202633$3.92B
Q1 202633$2.16B
Q4 202529$2.62B
Q3 202530$1.71B
Q2 202531$2.17B
Q1 202529$1.75B
Q4 202423$2.15B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 242 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BRKR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 4, 2026Analysis-
8-KOct 29, 2026Analysis-
4Sep 16, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
4Aug 18, 2026--
8-KAug 14, 2026Analysis-
4Aug 13, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
4Aug 11, 2026--
4Aug 11, 2026--
4Aug 11, 2026--
10-QAug 5, 2026-
8-KAug 4, 2026Analysis-
8-KJul 30, 2026Analysis-
4Jul 16, 2026--
4Jun 16, 2026--

Related Health Care companies

All Health Care →

BRKR SEC filings: frequently asked questions

Are BRKR insiders buying or selling?

In the last 90 days, Bruker Corp (BRKR) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $105,740 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold BRKR stock?

As of September 30, 2026, the largest Bruker Corp (BRKR) holders among the 13F filers tracked by SignalX were BlackRock ($763.4 million), Vanguard Portfolio Management LLC ($322.1 million), Vanguard Capital Management LLC ($314.7 million), State Street Corp ($259.4 million), T. Rowe Price Group ($238.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was BRKR's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Bruker Corp (BRKR) reported revenue of $3.4 billion (up 2.1% from FY2024) and a net loss of $8.6 million. Diluted EPS was -$0.15. The figures come from the XBRL data in the 10-K.

What did BRKR report in its latest 8-K?

Bruker Corp (BRKR) filed an 8-K on November 16, 2026 reporting Item 8.01 (Other Events) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Quarterly cash dividend: $0.05 per common share.

What are the latest BRKR SEC filings?

Bruker Corp (BRKR) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on September 16, 2026.

What is BRKR's SEC CIK number?

Bruker Corp (BRKR)'s SEC Central Index Key (CIK) is 1109354. EDGAR lists every BRKR filing under that number.

Ask anything about BRKR

The research agent reads BRKR's filings, financials, insider trades and 13F holders, then answers with sources.